FOSTER CITY, Calif. – Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or...
Latest News
Arlington, Texas – A multidisciplinary team of researchers that included 14 graduate students from The University of Texas at Arlington has created a new framework to provide optimal personalized treatment options for individuals with esophageal cancer. “Esophageal cancer is an unusually diverse disease with many heterogeneities and cancerous origins, which...
East Lansing, Michigan – Researchers at Michigan State University may have discovered why visceral pain is so common in people who have experienced inflammation in their guts, including patients with irritable bowel syndrome, or IBS. Working with mouse models, MSU physiologists showed that nervous system cells known as glia can...
BUFFALO, NY – A new research paper was published in Oncotarget’s Volume 14, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.” To evade cell cycle controls, malignant cells rely upon rapid expression of...
BUFFALO, NY- March 4, 2024 – A new research paper was published in Oncotarget’s Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed...
FOSTER CITY, Calif. — Gilead Sciences, Inc., today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC...
Gilteritinib may improve long-term outcomes, compared with salvage chemotherapy, in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), according to updated data from the ADMIRAL trial published in Blood. [1] The phase 3 ADMIRAL trial (ClinicalTrials.gov Identifier: NCT02997202) enrolled adults with FLT3-mutated AML who were in their first relapse after...
The family of a four-year-old girl with a rare genetic disorder are looking for auction and raffle prizes to help give something back to two charities that have helped her. Bethany Hepburn, of Washwood Close, Little Hulton, has Wolf Hirschhorn Syndrome, which severely restricts her development and has caused a...
Givinostat halted muscle shrinkage and fat infiltration in men with Becker muscular dystrophy (BMD) despite failing to ease muscle scarring, compared to a placebo, according to top-line, one-year results of an ongoing Phase 2 clinical trial. “We are very encouraged by the significant difference in muscle fat infiltration between the two groups after...
SEATTLE – According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027). Key Trends and Analysis: The increasing incidence of myeloproliferative neoplasm is expected...